e-learning
resources
Virtual 2020
Pre-Congress Content
Predictive markers of progression in connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
A new method to estimate the long-term effect of immunosuppressants and vasodilator therapies on lung function outcomes in systemic sclerosis patients
N. LE-DONG (Erpent, Belgium), T. Hua-Huy (Paris, France), T. Hoang-Thi (Paris, France), V. Codullo (Paris, France), Y. Allanore (Paris, France), A. Dinh-Xuan (Paris, France)
Source:
Virtual Congress 2020 – Predictive markers of progression in connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis
Session:
Predictive markers of progression in connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis
Session type:
E-poster session
Number:
807
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
N. LE-DONG (Erpent, Belgium), T. Hua-Huy (Paris, France), T. Hoang-Thi (Paris, France), V. Codullo (Paris, France), Y. Allanore (Paris, France), A. Dinh-Xuan (Paris, France). A new method to estimate the long-term effect of immunosuppressants and vasodilator therapies on lung function outcomes in systemic sclerosis patients. 807
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Panel discussion on genetics in pulmonary fibrosis
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Related content which might interest you:
Proof of concept study to evaluate step down therapy with inhaled corticosteroid alone or additive therapy on surrogate inflammatory markers in asthma
Source: Annual Congress 2010 - Pharmacological modulation of biomarkers and management
Year: 2010
The effect of augmentation therapy on systemic and pulmonary inflammation markers in α1-antitrypsin deficiency patients
Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in non-neoplastic and neoplastic lung diseases
Year: 2010
Low-dose amiodarone therapy may be responsible of serious adverse pulmonary effects in patients without pre-existing lung disease
Source: Eur Respir J 2004; 24: Suppl. 48, 280s
Year: 2004
Does azithromycin-prednisolone combination therapy have additive effects than single therapy in patients with persistent asthma?
Source: Annual Congress 2009 - Aspects of uncontrolled asthma
Year: 2009
A rejuvenation effect of the antifibrotic therapy correlates with lung function improvement in IPF patients
Source: Virtual Congress 2021 – Novel insights into the pathogenesis of chronic lung diseases
Year: 2021
Is there a benefit of an additive standard immunoglobulin therapy for the clinical course of COPD patients under chronic immunosuppressive therapy?
Source: Eur Respir J 2001; 18: Suppl. 33, 24s
Year: 2001
Real-world antifibrotic treatment persistence and clinical outcomes for patients with idiopathic pulmonary fibrosis
Source: Virtual Congress 2021 – Interstitial lung disease around the world
Year: 2021
Hemodynamic phenotypes in systemic sclerosis patients screened for pulmonary hypertension – impact of the new PH-definition
Source: International Congress 2019 – Pulmonary arterial hypertension: recent advances from the bedside
Year: 2019
Omalizumab improves asthma control in patients receiving high-dose ICS and multiple other controller therapies and who have continuing impairment of lung function and asthma symptoms
Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities
Year: 2007
Small airways function: evaluation in a population of adult patients with severe asthma and potential use as a response biomarker for anti-IL5 therapy
Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma
Year: 2020
The effect of prednisone treatment on lung function test parameters in patients with chronic sarcoidosis
Source: Eur Respir J 2002; 20: Suppl. 38, 433s
Year: 2002
Exercise pulmonary haemodynamics predict outcome in patients with systemic sclerosis
Source: Eur Respir J 2016; 48: 1658-1667
Year: 2016
Correlation of response to antifibrotic treatment with adverse events to antifibrotic drugs in IPF patients from the real-world EMPIRE registry
Source: Virtual Congress 2020 – Translational aspects of idiopathic pulmonary fibrosis
Year: 2020
COVID-19 risk and outcomes in adult asthmatics treated with biologics or systemic corticosteroids: nationwide real-world evidence.
Source: Virtual Congress 2021 – Asthma treatment: clinical and translational science
Year: 2021
Long-term outcomes of antifibrotic treatments in patients with idiopathic pulmonary fibrosis: Real-world experience
Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries
Year: 2020
Does atorvastatin have effect on lung function and morbidity as add-on therapy in asthmatic patients?
Source: Annual Congress 2007 - New drugs for asthma
Year: 2007
Pulmonary and systemic inflammatory response in patients with pulmonary infections receiving long-term glucocorticoid therapy
Source: Eur Respir J 2002; 20: Suppl. 38, 15s
Year: 2002
Response to PAH specific therapy in systemic sclerosis patients with extensive parenchymal changes and pulmonary hypertension
Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases
Year: 2020
Comparative analysis of the efficacy of glucocorticosteroids and antimetabolite drugs in treatment of patients with pulmonary sarcoidosis
Source: International Congress 2019 – Granulomatous disorders: pathogenesis, epidemiology and clinical issues
Year: 2019
The change of lung diffusion capacity does not influence the prognosis in patients with pulmonary arterial hypertension associated with systemic sclerosis.
Source: International Congress 2019 – Endpoints and risk assessment of pulmonary arterial hypertension
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept